Overall, cancer institutions in the United States have significant advantages in drug research and development, as well as access to new medications. Treatment options are more diverse, and the medical experience is generally excellent. However, cancer treatment in the U.S. often requires appointments, which may involve long waiting times, and the costs are relatively high.
In China, basic cancer treatment needs are generally met, with the advantage of higher efficiency. For rare and complex diseases, the U.S. has clear advantages. For minor illnesses or early-stage treatments, especially for surgeries based on experience, Chinese treatment institutions might have an edge.
